SynCore Biotechnology Co.,Ltd (TPEX:4192)
20.10
-0.35 (-1.71%)
Apr 1, 2026, 2:31 PM CST
TPEX:4192 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 157.33 | 205.49 | 264.7 | 269.15 | 552.97 |
Trading Asset Securities | 7.07 | 6.96 | 6.66 | 6.66 | 6.66 |
Cash & Short-Term Investments | 164.41 | 212.44 | 271.36 | 275.81 | 559.63 |
Cash Growth | -22.61% | -21.71% | -1.61% | -50.72% | 2.52% |
Accounts Receivable | 6.14 | 2.37 | 2.7 | 1.91 | 1.81 |
Other Receivables | - | 32.78 | 31.69 | 30.87 | 30.27 |
Receivables | 6.14 | 35.15 | 34.4 | 32.78 | 32.08 |
Inventory | 9.68 | 10.06 | 3.13 | 36.4 | 114.04 |
Prepaid Expenses | 34.8 | 2.39 | 1.46 | 2.71 | 3.73 |
Other Current Assets | 0.24 | 0.42 | 0.13 | 0.54 | 1.22 |
Total Current Assets | 215.26 | 260.46 | 310.48 | 348.23 | 710.71 |
Property, Plant & Equipment | 3.01 | 9.48 | 4.63 | 14.81 | 11.12 |
Long-Term Investments | - | 3.91 | 12.08 | 15.09 | 20.36 |
Other Intangible Assets | 36.99 | 43.89 | 51.11 | 58.47 | 82.21 |
Other Long-Term Assets | 0.45 | 0.06 | 0.06 | 0.04 | 0.04 |
Total Assets | 255.7 | 317.8 | 378.36 | 436.65 | 824.44 |
Accounts Payable | 1.2 | 9.51 | 0.16 | 0.87 | 0.16 |
Accrued Expenses | - | 3.93 | 16.96 | 114.13 | 252.26 |
Short-Term Debt | - | - | - | 60 | 120 |
Current Portion of Leases | 1.95 | 6.8 | 1.95 | 10.21 | 5.3 |
Current Unearned Revenue | 0.83 | - | - | - | - |
Other Current Liabilities | 6.09 | 1.89 | 2.15 | 1.43 | 3.8 |
Total Current Liabilities | 10.07 | 22.12 | 21.23 | 186.64 | 381.52 |
Long-Term Leases | - | 0.99 | - | 0.99 | - |
Total Liabilities | 10.07 | 23.11 | 21.23 | 187.64 | 381.52 |
Common Stock | 351.65 | 351.65 | 351.65 | 1,151 | 1,151 |
Additional Paid-In Capital | 12.62 | 66.91 | 105.08 | - | 263.5 |
Retained Earnings | -82.32 | -54.28 | -38.17 | -843.33 | -918.16 |
Comprehensive Income & Other | -36.33 | -69.58 | -61.42 | -58.43 | -53.19 |
Shareholders' Equity | 245.63 | 294.69 | 357.14 | 249.01 | 442.92 |
Total Liabilities & Equity | 255.7 | 317.8 | 378.36 | 436.65 | 824.44 |
Total Debt | 1.95 | 7.79 | 1.95 | 71.2 | 125.3 |
Net Cash (Debt) | 162.46 | 204.66 | 269.4 | 204.6 | 434.34 |
Net Cash Growth | -20.62% | -24.03% | 31.67% | -52.89% | 36.84% |
Net Cash Per Share | 4.62 | 5.82 | 8.40 | 6.65 | 14.31 |
Filing Date Shares Outstanding | 35.29 | 35.17 | 35.17 | 30.74 | 30.74 |
Total Common Shares Outstanding | 35.29 | 35.17 | 35.17 | 30.74 | 30.74 |
Working Capital | 205.19 | 238.34 | 289.26 | 161.59 | 329.19 |
Book Value Per Share | 6.96 | 8.38 | 10.16 | 8.10 | 14.41 |
Tangible Book Value | 208.64 | 250.79 | 306.03 | 190.54 | 360.71 |
Tangible Book Value Per Share | 5.91 | 7.13 | 8.70 | 6.20 | 11.73 |
Machinery | - | 39.41 | 39.2 | 38.78 | 39.53 |
Leasehold Improvements | - | 18.38 | 18.38 | 18.38 | 18.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.